Expression of MDM2, p65, and Sp1 proteins and sensitivity to doxorubicin in primary leukemia cells from 10 randomly selected patients with BCP-ALL.

(A) Expression of MDM2, p65, and Sp1 proteins in marrow mononuclear cells (more than 90% leukemic blasts) from pediatric patients with ALL was analyzed by Western blot assay. (B) Response to doxorubicin of leukemic cells from the same samples examined for MDM2, p65, and Sp1 protein expression. Cells were cultured with doxorubicin at 1 μM for 48 hours, and cell survival (viability) was determined by XTT assay. Viability was expressed as percentage of control (ie, cultures without doxorubicin). Data represent mean ± SD detected in triplicate experiments. UPN, unique patient number.